Transcript Market Analysis - Ventac Partners

Driving Innovation and Strategic
Excellence in Life Sciences
www.ventac-partners.com
About Ventac Partners
We Are Experts in Life Science Business Development
Consulting Services
We provide experience-based consulting services for Biotech, Pharma and
Medtech clients globally. Technical consulting, project management,
strategy & management consulting, market & opportunity analyses are
some of our core areas of expertise.
Corporate Development
We offer extensive buy and sell-side transaction experience with a truly
international reach in virtually all Life Science sectors. Our specialties
include in- and out-licensing, mergers & acquisitions, business
development and marketing collaborations in all continents.
Company Creation
Ventac Partners has a global network of Life Science investors in Europe,
US and Asia as well as expertise in founding and growing companies on
behalf of clients. Unlike other consulting agencies, we also form, manage,
grow and help exit innovative Portfolio Companies co-owned with partners
& investors.
Why Use Ventac for Your Consulting Needs?
We Bring Real-world, Current Experience to Address Your Analytical and Operational Needs
• Global Operational Experience
• Strong Track Record for Product and Company Launches
• Expertise from Concept to Commercialization
• Market & IP Research
• Competitive & Pipeline Analysis
• Direct Market Feedback from Key Opinion Leaders
• Due Diligence
• Business Development
• Product Development & Launch
Market Analysis
A service offering that provides comprehensive analysis and insights into the current
and future market and competitors
•
Determine
barriers to
market entry
Market
opportunity for
new/existing
products or
markets
▫
Secondary sources
▫
Proprietary database and reports
(Globaldata)
Assess size of
opportunity
▫
Analyst reports
•
Comprehensive analysis from
defined data sources
Market/
•
Data validation and quality checks
Opportunity
•
Customized reports that deliver
strategic insights and market
highlights most relevant to client
needs
Assessments
4
Data Collection Sources:
Market Analysis – Project Approach
Methodology Development &
Project Outline
Data Collection and
Integrated Analysis
Disease
Overview
Market Size
Estimation
Consultation with Client
Market
Attractiveness
Epidemiology
Add Value Analysis/Research
Draft Report Analysis and
Presentation
Further Consultation with the
Client
Final PowerPoint Presentation
5
Current
Treatment
Options
Future Outlook
Pipeline
Analysis/
Competitive
Landscape
Unmet
Needs
Current
Market
Landscape
with Trend
Analysis
Competitive Intelligence
•
CI services address the need of a
client to receive relevant, quick and
important competitive information
about competitive threats, business
opportunities as well as market
scenarios
Range of CI Service Offerings
Pipeline Analysis
•
Services offered across a wide range
of therapeutic areas
Molecule Profiling
•
The CI solution portfolio organizes and
analyzes information from various
sources to deliver insights that help
management take important tactical
and strategic decisions
Clinical Trial Maps
Company/Product
Profiling
Therapy Area
Analysis
Disease Area Strategy
Analysis
6
Pipeline Analysis
Client files
Pipeline and other
relevant information
from proprietary
databases that client has
access to
Collate a list of
pipeline molecules
by indication
Organize and filter
project specific
information
Secondary sources
• Clincaltrials.gov
• Pubmed
• Cancer.gov
• Company websites
▫ Competitive grid:
A tabular representation to highlight
the number of competitive molecules
by phase of development among
indications of interest, allowing for
top-line views and comparison
▫ Bullseye chart:
Molecule Name
Sort and analyze
pipeline
information
Phase of Development
Company Name
Drug Class
An organized system that graphically
represents the molecules in
development for each indication
▫ Detailed molecule profiles:
Competitive
Grid
Bubble
Chart
Project Outputs
7
In-depth
molecule
profile
Profiling of late-stage molecules of
interest to the client for each of the
indications requested
Bullseye Chart - Molecules in Development
by Phase of Development and Drug class
Drug Class G
Phase I
Drug 1
Phase II
Drug Class A
Drug 2
Drug Class F
Drug 4
Drug 2
Drug 3
Phase III
Drug 1
Drug 2
Drug 3
Drug 1
Regulatory
Approval
Drug 3
Drug 1
Drug Class B
Drug 3
Drug 2
Drug 2
Drug 7
Drug 1
Drug 6
Drug 8
Drug 5
Drug 9
Drug Class E
Drug 10
Drug 11
Drug 1
Drug 2
Drug 4
Drug 3
Drug 1
Drug Class C
Drug 6
Drug 3
Drug 2
Drug 4
Drug 5
Drug Class D
Pipeline Tracking and Analysis
Clearly presented results coupled with strategic
insights and recommendations
Pipeline Tool
PowerPoint
Reports
9
Product Profiling
Research Scope
1.
2.
3.
4.
5.
6.
Secondary
Searches
Annual Reports
Analyst Reports
Investor Relation
reports
KOL Interviews
Proprietary
Databases
10
•
Total Sales
•
Product Strength
•
Product Risk Assessment
•
Competitive Landscape
•
Latest News
•
Sales forecast
A Word/PowerPoint report providing detailed and customized profiling of in-market products across
parameters defined by client
Molecule Profiling
•
•
•
•
•
•
Current phase of development for each indication
Originator/Licensee(s)
Mechanism of Action
Route of Administration
Safety & Efficacy report
Developmental History
Detailed profiles with latest clinical study results and ongoing trials
11
Third Party IP/FTO Assessment
•
Review of initial Freedom to Operate
search - outsourced to searching
experts) to identify potentially
problematic granted and in-force
patents and pending patent
applications
•
Technical assessment of main patent
documents of concern in conjunction
with client technical experts
•
If necessary and approved, assistance
with assessment of potential
infringement and validity of identified
patents/applications with appropriate
patent attorneys in the relevant
territories
Third Party IP Assessment
Outsourced Search
Review of Results
Problem Patents
Law Firm Opinion
Assessment of
Relevance/Risk
Strategic
Recommendations
12
Our Presence
We have access to the expertise of our 19 partners across the globe. Specific partners are
chosen for a project based on individual expertise.
Trondheim
Lund
Boulder
San Francisco
San Diego
Boston
London
Düsseldorf
Basel
Madrid
Copenhagen
Munich
Shanghai
Our International Team
Scott Mikael
Woodward Ørum
Martin
Austin
Robert
Buchanan
Dede
Willis
Peter
Damsbo
Melya Hughes
Crameri
Jonathan
Myers
Lars
Hedbys
Pharma – Biotech – Medtech
Rolf
Ehrnstrom
Neil
Thomas
Aarti
Kapoor
Kostas
Alevizopoulos
Dennis
Henriksen
Randi
Berholtz
Henrik
Stage
Joe
Tucker
Mirko
Stange
Bengt
Westrin
Track Record Summary
•
Our team offers more than 300 years of international experience in growing
technology into successful businesses, both as entrepreneurs in start-up
companies and as senior managers in pharma, biotech and CROs. Since the
foundation of Ventac Partners in 2002, the team has:
– assessed more than 1000 invention disclosures and business plans from life science
researchers and entrepreneurs
– raised more than EUR 250 million in funding for start-up and growth stage companies
– incorporated and grown more than 15 spin-out companies with
inventors/universities/large companies as co-owners
– negotiated large technology and drug licenses in USA, Europe, Japan and China
– provided board level strategic input to companies and governments
– delivered turn-around teams to companies in distress or in need of a sharper
commercial profile and/or successful business development impact in the market
place
15
Driving Innovation and Strategic
Excellence in Life Sciences
www.ventac-partners.com